Microglia and brain macrophages: An update
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Current immunohistochemical techniques have made the identification of microglia possible in routinely processed tissue sections from human brains. Previous studies have indicated that almost no neurological diseases exist without microglial activation. Activated microglia often secrete inflammatory cytokines in various diseases, including Alzheimer's disease, but microglial activation is not always associated with inflammation. The equation microglial activation means “neuroinflammation” is absurd and misleading. Neuropathologists are in the best position to provide clarity to end the existing confusion. The functions of microglia in the non‐diseased brain probably include a role in synaptic maintenance, but defects in the expression of specific molecules on microglia can also cause leukoencephalopathy, such as Nasu‐Hakola disease (NHD) and hereditary leukoencephalopathy with spheroids (HDLS). “Microgliopathies” is a new term used to designate conditions where microglial dysfunction is primary and at the center of the disease process. The molecules responsible are DAP12 or TREM2 in NHD and CSF1R in HDLS, respectively, but further studies are needed to clarify how exactly these microglial molecules influence the pathogenesis of axonal and myelin loss. Diffusely infiltrating glial tumors showing microglial differentiation (true microglioma) are exceedingly rare but recent evidence suggests that they indeed exist, although their molecular genetic characterization is still lacking. Participation of the expert neuropathology community will be required to identify additional cases and provide the latter. A large number of tumor‐associated macrophages (TAMs), which are partly derived from microglia, have been observed in glioblastomas. In TAMs, the expression of M2‐like molecules is higher than that of M1‐like molecules, but the number and differentiation state of TAMs vary in the intratumoral area and with the type of macrophage markers used. In future studies, we should focus on the morphological and molecular alterations of the microglia that are specific to the disease where they are observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Yona, S., Kim, K.-W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., Guilliams, M., Misharin, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.001 · Cited by 3,245 · cited 1×
“CX3CR1 does not represent a microgliaspecific marker either in both the naïve brain or in the context of glioma.(94,106,107) Tissue-resident macrophages can be distinguished by their gene expression patterns.”
BackgroundAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 1×
“CSF-1R inhibition in a mouse proneural GB model increased survival and shrank established tumors, and Stat3 inhibition has been shown to activate tumor macrophages and abrogates glioma growth in mice.(114) Additionally, local delivery of minocycline and systemic 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) have syner…”
BackgroundTissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., Jung, S., & Amit, I. (2014) · Cell · doi:10.1016/j.cell.2014.11.018 · Cited by 2,167
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · cited 1×
“From the in vitro data, it is suggested that the TREM2-DAP12molecule-signaling complex is required in microglial cells to removemacromolecules and apoptotic cells.(66,67) Currently, very little is known about the specific molecules involved in the phagocytosis of each target by microglia, as the ligand of TREM2 remain…”
BackgroundBrain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“diseases has been determined and the neuroinflammatory hypothesis of neurodegeneration has been established.(38,39)”
BackgroundThe role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683 · cited 2×
“ies have suggested a correlation between M1-specific markers or associated pathways and glioma growth.(23) IL-”
BackgroundWake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S., & Nabekura, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-08.2009 · Cited by 1,619
Microglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Zhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A. E., McLendon, R. E., Li, X., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3090 · Cited by 940
Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1112 · Cited by 872 · cited 1×
“microglial markers, ionized calcium binding adapter molecule 1, Iba1, is the most robust marker for microglia in paraffin-embedded sections of human brains, although Iba1 labels other types of macrophages in the body in addition to microglia.(26,27) Iba1 is advantageous for morpho-”
BackgroundMogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
CSF-1 regulation of the wandering macrophage: complexity in action
Pixley, F. J., & Stanley, E. R. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.016 · Cited by 807 · cited 1×
“CSF1 and its receptor, CSF1R, play a key role in microglial homeostasis in mice in vivo.(69) Thus, HDLS could be categorized as another “microgliopathy”.”
BackgroundInternational MS Genetics Consortium, De Jager, P. L., Jia, X., Wang, J., de Bakker, P. I. W., Ottoboni, L., Aggarwal, N. T., Piccio, L., Raychaudhuri, S., Tran, D., et al. (2009) · Nature Genetics · doi:10.1038/ng.401 · Cited by 800
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738 · cited 1×
“CD163+ M2-TAMs and CD204+ M2-TAMs were more closely related to poor prognosis than CD68+ TAMs in gliomas.(22,93) In our experience, the number of CD204+ TAMs is slightly higher than that of CD163+ TAMs in many GB”
BackgroundPaloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 2×
“The molecular background of NHD was characterized by identifying mutations in two genes: DAP12, also known as TYRO protein tyrosine kinasebinding protein (TYROBP) and TREM2.”
BackgroundGraeber, M. B. (2010) · Science · doi:10.1126/science.1190929 · Cited by 608 · cited 1×
“Also important, synaptic maintenance (synaptic pruning, removal of synaptic debris) by microglia in the normal CNS begins during development and persists throughout life.(118) Even in a normal state, microglia are not “resting” but are highly active and in a “surveillance”
BackgroundWild-type microglia arrest pathology in a mouse model of Rett syndrome
Derecki, N. C., Cronk, J. C., Lu, Z., Xu, E., Abbott, S. B. G., Guyenet, P. G., & Kipnis, J. (2012) · Nature · doi:10.1038/nature10907 · Cited by 607
Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis
Sierra, A., Abiega, O., Shahraz, A., & Neumann, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00006 · Cited by 574
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433
Wakselman, S., Béchade, C., Roumier, A., Bernard, D., Triller, A., & Bessis, A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1006-08.2008 · Cited by 351 · cited 1×
“In themurineCNS,DAP12 expression is localized in microglia.(59,60) In the human CNS, DAP12 is expressed on ramified microglia and activated microglia, with greater expression in the latter cells in both healthy and diseased brains (Fig.”
BackgroundStreit, W. J., Xue, Q.-S., Tischer, J., & Bechmann, I. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0142-6 · Cited by 317 · cited 4×
“Interestingly, rare mutation of genes for immune receptors, including TREM2 and CD33, were associated with an increased risk of late-onset AD.74–76 Microgliopathy does not imply a total loss or marked decrease of the number of microglial cells in the CNS.”
BackgroundInfluentialOtero, K., Turnbull, I. R., Poliani, P. L., Vermi, W., Cerutti, E., Aoshi, T., Tassi, I., Takai, T., Stanley, S. L., Miller, M., et al. (2009) · Nature Immunology · doi:10.1038/ni.1744 · Cited by 315
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301 · cited 1×
“lapping function and form a continuum rather than two distinct states.(97)”
BackgroundNeumann, H., & Takahashi, K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.032 · Cited by 249
Sessa, G., Podini, P., Mariani, M., Meroni, A., Spreafico, R., Sinigaglia, F., Colonna, M., Panina, P., & Meldolesi, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03729.x · Cited by 165
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162 · cited 1×
“The study of “dystrophic” microglia and their potential importance in neurodegenerative disease pathogenesis is in progress.(54) NHD, or lipomembranous osteodysplasia with sclerosing”
BackgroundKiialainen, A., Hovanes, K., Paloneva, J., Kopra, O., & Peltonen, L. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.007 · Cited by 114 · cited 1×
“In themurineCNS,DAP12 expression is localized in microglia.(59,60) In the human CNS, DAP12 is expressed on ramified microglia and activated microglia, with greater expression in the latter cells in both healthy and diseased brains (Fig.”
BackgroundThe International Multiple Sclerosis Genetics Consortium (2011) · PLoS ONE · doi:10.1371/journal.pone.0018813 · Cited by 74
Cited by
van der Knaap, M. S., & Bugiani, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1739-1 · Cited by 403
Chu, F., Shi, M., Zheng, C., Shen, D., Zhu, J., Zheng, X., & Cui, L. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.02.015 · Cited by 303
Artegiani, B., Lyubimova, A., Muraro, M., van Es, J. H., van Oudenaarden, A., & Clevers, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.050 · Cited by 259
“…primed in two ways: the canonical M1 priming state promotes inflammation and the consequent neurotoxicity, and the alternative M2 priming state has an anti-inflammatory function aimed at restoring homeostasis and promoting regeneration (Cherry et al., 2014; Prinz and Priller, 2014; Sasaki, 2017).”
BackgroundDiagnosis, prognosis, and treatment of leukodystrophies
van der Knaap, M. S., Schiffmann, R., Mochel, F., & Wolf, N. I. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30143-7 · Cited by 175
TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94
Metadata
- Authors
- Sasaki, A.
- Venue
- Neuropathology
- Publisher
- Wiley
- Published
- 2016-11-18
- Volume
- 37
- Issue
- 5
- Pages
- 452-464
- ISSN
- 0919-6544 (ISSN-L)
- 1440-1789
- OpenAlex
- W2555895139
- Cited by
- 92
- References
- 34
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.